Other Events ·
Veru advances sabizabulin into Phase 2b trial for metastatic pancreatic cancer, halts development for cardiovascular inflammation
VERUVeru Inc.
On September 8, 2026, Veru Inc. announced it will advance its oral drug candidate sabizabulin into a planned Phase 2b clinical trial for metastatic pancreatic cancer resistant to daraxonrasib (RASONQUE). This strategic pivot follows positive preclinical data showing sabizabulin's potent anticancer activity in daraxonrasib-resistant KRAS-driven cell lines. Consequently, the company will cease development of sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease. Veru plans to seek regulatory clarity via an FDA pre-IND meeting in Q4 2026. Additionally, the Phase 2b PLATEAU trial for enobosarm is fully enrolled with interim analysis expected in Q1 2027. Veru Inc. operates as a late-stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and oncology indications.